Tagged with Swiss

Mexico The Swiss Chamber in Mexico (SwissCham) represents Swiss companies operating in Mexico, a country that has become Switzerland’s top commercial partner in Latin America. Executive Director Emilia Pfeiffer outlines the role of SwissCham, the robust presence of the Swiss healthcare and life sciences companies in the country, the Chamber’s advocacy…

Switzerland While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of…

Switzerland For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World Health Organisation (WHO), Swissmedic also saw a Good Manufacturing Practice (GMP) agreement between Switzerland and the US FDA come into…

Europe Sparks, the Swiss Exchange’s newly launched small and medium sized enterprise (SME) trading venue, intends to make it easier for biotech SMEs to raise capital and strengthen their profile. The Swiss biotech sector has proven to be attractive for investors, with venture capital investments rising almost steadily over the past…

Europe The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly beyond COVID-19. According to the Swiss Biotech Report presented at the Swiss Biotech Day 2022 in Basel, the sector experienced…

Turkey Dogan Taskent, board member of the Swiss Chamber of Commerce in Turkey, highlights Turkey’s successful response to the COVID-19 pandemic, how the local R&D ecosystem collaborated, often for free, to develop vaccines and treatments, one of which is currently in phase III clinical trials. In addition, Taskent analyzes the Turkish…

Switzerland This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some of its most exciting companies. Download here.   2020 stands out as having been the best year yet for Swiss…

Switzerland Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs, notably COVID-19 vaccines. Although its approval times are increasing, raising doubts about Swissmedic’s continued place at the top table of…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Switzerland Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the country’s ecosystem has helped foster success stories like Actelion, and the multilateral work being done to improve intellectual property protection…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Switzerland Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs. Although its approval times are increasing, raising doubts about Swissmedic’s continued place at the top table of global regulators, initiatives…